Auro Laboratories Limited (530233) fair value: what the stock is really worth
As of Nov 20, 2026: fair value (intrinsic value) of Auro Laboratories Limited stock ₹94.19, price ₹247.60, that is 62.0% below the price, quality 43 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Auro Laboratories Limited
530233 · BSEFar too expensive (fair value 62% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 22, 2026.
How to read this chart
60‑month range ₹54.08 – ₹302.05 · fair‑value band ₹65.93 – ₹122.44 · the ₹247.60 price screens above the ₹94.19 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 22, 2026.
Every Wednesday you see whether Auro Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India.
Show moreShow less
It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose.
The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and trimethoxy benzoic acid.
In addition, it offers intermediates consisting of glibenclamde sulphonamide for use in API glibenclamide; cis-bramo benzoate and cls-tosylate that are used in API Ketoconazol; trimethoxy benzoic acid; 2-ethoxy benzoic acid for use in API sildenafil citrate; and 5-bromo phthalide that is used in API citalopram.
It also exports products to Egypt, Germany, Malaysia, Singapore, South Africa, Brazil, Spain, and the United Kingdom. Auro Laboratories Limited was incorporated in 1989 and is based in Mumbai, India.
Stock analysis
Auro Laboratories Limited (530233) currently trades at ₹247.60, while our model-based Fair Value estimate is ₹94.19, 62% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹110.81 per share, and 0 of the 12 models we run sit above the ₹247.60 price.
Bear case: the Economic Profit group reads lowest at ₹31.97, and 12 of the 12 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹65.93 (bear) to ₹122.44 (bull), the price of ₹247.60 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 43/100 (below-average quality), in the Health Care sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Auro Laboratories Limited reported revenue of ₹307M in FY2026 versus ₹509M in FY2022, a compound −11.8%/yr. Reported net income was ₹35.3M in FY2026, compounding +5.6%/yr from FY2022.
Key figures
Market cap ₹531M (≈ $5.7M) Micro · P/E ratio 10.2 · P/S ratio 1.14 · EPS (TTM) ₹8.26 · Net margin 11.1% · Return on equity 22.8% · Return on assets (EBIT) 6.4% (5-year average) · Operating margin 14.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Health Care peers we cover trades at −33% fair-value upside, at −62%, 530233 screens richer than that median.
Fair Value models
All 12 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
530233 screens overvalued: fair value 62% below the price. Compare with Mezzion Pharma Co →
Compare Auro Laboratories Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 56 stocks
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on equity by industry
- Quality Score by industry
- Stock screener with 62 metrics
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Huons Global Co 084110 | ₩19,140 | ₩47,019 | +146% | vs 530233 |
| DongKook Pharmaceutical Co 086450 | ₩25,250 | ₩28,372 | +12% | vs 530233 |
| ST Pharm Co 237690 | ₩71,600 | ₩61,182 | −15% | vs 530233 |
| Vivozon Pharmaceutical Co 082800 | ₩2,650 | ₩1,939 | −27% | vs 530233 |
| Oscotec Inc 039200 | ₩31,650 | ₩21,262 | −33% | vs 530233 |
| NatureCell Co 007390 | ₩20,250 | ₩10,573 | −48% | vs 530233 |
| Mezzion Pharma Co 140410 | ₩61,200 | ₩29,689 | −51% | vs 530233 |
| BINEX Co 053030 | ₩7,000 | ₩1,844 | −74% | vs 530233 |
| Caregen Co 214370 | ₩26,700 | ₩5,414 | −80% | vs 530233 |
| SHUKRAPHAR SHUKRAPHAR | ₹82.22 | ₹9.14 | −89% | vs 530233 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Auro Laboratories Limited (530233) overvalued or undervalued?
What is the fair value of 530233?
What is the quality score of 530233?
What is the price target for Auro Laboratories Limited (530233)?
What is the Auro Laboratories Limited stock forecast for 2026?
What is the revenue of Auro Laboratories Limited (530233)?
What is the intrinsic value of Auro Laboratories Limited (530233)?
Is Auro Laboratories Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 530233?
How much is Auro Laboratories Limited worth?
What do the bullish and bearish scenarios say about 530233?
What is the P/E ratio of 530233?
How solid is the balance sheet of Auro Laboratories Limited (530233)?
How far is 530233 from its 52-week high?
Which stocks are comparable to Auro Laboratories Limited?
Is Auro Laboratories Limited stock attractive at the current price?
How is the fair value of 530233 calculated?
Is it still worth investing in stocks now?
What is the share price of Auro Laboratories Limited (530233)?
What should I pay attention to with Auro Laboratories Limited right now?
Key figures of Auro Laboratories Limited
How large is the market capitalisation of Auro Laboratories Limited (530233)?
What is the P/S ratio of Auro Laboratories Limited (530233)?
What are the earnings per share of Auro Laboratories Limited (530233)?
What is the net margin of Auro Laboratories Limited (530233)?
What is the return on equity of Auro Laboratories Limited (530233)?
What is the EBIT return on assets of Auro Laboratories Limited (530233)?
What is the operating margin of Auro Laboratories Limited (530233)?
How fast is revenue growing at Auro Laboratories Limited (530233)?
How fast are earnings growing at Auro Laboratories Limited (530233)?
How much free cash flow does Auro Laboratories Limited (530233) generate?
How much net debt does Auro Laboratories Limited (530233) carry?
Watch Auro Laboratories Limited in the live analysis
One click puts Auro Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.